![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The New-Generation Biotherapeutic (NGB) drug candidate, HBI-06, has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
Lead Product(s): HBI-06
Therapeutic Area: Infections and Infectious Diseases Product Name: HBI-06
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023